RS61760B1 - Režimi doziranja amisulprida za lečenje mučnine i povraćanja - Google Patents

Režimi doziranja amisulprida za lečenje mučnine i povraćanja

Info

Publication number
RS61760B1
RS61760B1 RS20210407A RSP20210407A RS61760B1 RS 61760 B1 RS61760 B1 RS 61760B1 RS 20210407 A RS20210407 A RS 20210407A RS P20210407 A RSP20210407 A RS P20210407A RS 61760 B1 RS61760 B1 RS 61760B1
Authority
RS
Serbia
Prior art keywords
amisulpride
antiemetic
injectable
phase
kit
Prior art date
Application number
RS20210407A
Other languages
English (en)
Serbian (sr)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Gabriel Fox
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of RS61760B1 publication Critical patent/RS61760B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20210407A 2015-04-10 2016-04-11 Režimi doziranja amisulprida za lečenje mučnine i povraćanja RS61760B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506116.1A GB201506116D0 (en) 2015-04-10 2015-04-10 Kit and combination therapy for nausea and vomiting
EP16716659.4A EP3280392B1 (en) 2015-04-10 2016-04-11 Dosage regimens of amisulpride for treating nausea and vomiting
PCT/GB2016/050998 WO2016162695A1 (en) 2015-04-10 2016-04-11 Combinations of amisulpride and another anti-emetic for treating nausea and vomiting

Publications (1)

Publication Number Publication Date
RS61760B1 true RS61760B1 (sr) 2021-05-31

Family

ID=53333601

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210407A RS61760B1 (sr) 2015-04-10 2016-04-11 Režimi doziranja amisulprida za lečenje mučnine i povraćanja

Country Status (22)

Country Link
US (1) US10322106B2 (enExample)
EP (1) EP3280392B1 (enExample)
JP (1) JP6812360B2 (enExample)
KR (2) KR102711661B1 (enExample)
CN (1) CN107872975A (enExample)
AU (1) AU2016246104B2 (enExample)
CA (1) CA2982251C (enExample)
CY (1) CY1124184T1 (enExample)
DK (1) DK3280392T3 (enExample)
ES (1) ES2866933T3 (enExample)
GB (1) GB201506116D0 (enExample)
HR (1) HRP20210624T1 (enExample)
HU (1) HUE054165T2 (enExample)
IL (2) IL295650A (enExample)
LT (1) LT3280392T (enExample)
MX (1) MX388735B (enExample)
PL (1) PL3280392T3 (enExample)
PT (1) PT3280392T (enExample)
RS (1) RS61760B1 (enExample)
SI (1) SI3280392T1 (enExample)
SM (1) SMT202100216T1 (enExample)
WO (1) WO2016162695A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501285A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
JP2026526054A (ja) 2023-07-13 2026-08-04 アコンカグア・バイオ・インコーポレイテッド 化合物、組成物、および方法
EP4743174A1 (en) 2023-07-13 2026-05-20 Aconcagua Bio, Inc. CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
EP4771001A1 (en) 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026096926A1 (en) 2024-11-01 2026-05-07 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026156091A1 (en) 2025-01-15 2026-07-23 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003962D0 (en) 2010-03-10 2010-04-21 Tangentix Ltd Multimedia content delivery system
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
WO2013040164A1 (en) * 2011-09-13 2013-03-21 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders

Also Published As

Publication number Publication date
SMT202100216T1 (it) 2021-05-07
GB201506116D0 (en) 2015-05-27
SI3280392T1 (sl) 2021-08-31
KR20240125705A (ko) 2024-08-19
ES2866933T3 (es) 2021-10-20
DK3280392T3 (da) 2021-03-08
CA2982251C (en) 2023-06-13
LT3280392T (lt) 2021-04-26
JP2018510898A (ja) 2018-04-19
JP6812360B2 (ja) 2021-01-13
IL295650A (en) 2022-10-01
HUE054165T2 (hu) 2021-08-30
HRP20210624T1 (hr) 2021-05-28
US20180071249A1 (en) 2018-03-15
PT3280392T (pt) 2021-03-12
EP3280392A1 (en) 2018-02-14
AU2016246104A1 (en) 2017-11-30
MX388735B (es) 2025-03-20
US10322106B2 (en) 2019-06-18
HK1250913A1 (en) 2019-01-18
CA2982251A1 (en) 2016-10-13
PL3280392T3 (pl) 2021-10-18
WO2016162695A1 (en) 2016-10-13
CN107872975A (zh) 2018-04-03
KR102711661B1 (ko) 2024-10-02
CY1124184T1 (el) 2022-07-22
KR20180016350A (ko) 2018-02-14
MX2017012991A (es) 2018-02-01
EP3280392B1 (en) 2021-02-24
AU2016246104B2 (en) 2018-12-13
IL254929A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
JP6812360B2 (ja) 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
KR101738201B1 (ko) 구토방지제로서의 아미설프라이드의 용도
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
WO2008070795A2 (en) Combination therapy using low-dose doxepin for the improvement of sleep
JP2015511213A (ja) 薬物送達技術
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2020506209A (ja) 術後悪心嘔吐の救急治療
MX2011001631A (es) Tratamiento de transtornos de ansiedad.
JP3521143B2 (ja) グラニセトロンおよびデキサメタゾン含有の医薬組成物
KR20150095773A (ko) 건선 치료를 위한 피도티모드의 사용
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
HK1250913B (en) Dosage regimens of amisulpride for treating nausea and vomiting
JPS6058726B2 (ja) プリン誘導体を有効成分として含有する抗アレルギ−,鎮痛,鎮静剤
NZ192398A (en) Control of pain using a composition with a non-narcotic analgesic and l-methyl-4-(2-thienylcarbonyl)benzene acetic acid
JP2006028144A (ja) 末梢血行障害による不定愁訴の治療剤
TH81578A (th) การรวมกันของโรฟลูมิลาสท์และตัวยับยั้งอินทีกรินและวิธีการของการบำบัด